Home > Medicine & Health Science textbooks > Clinical and internal medicine > Diseases and disorders > Oncology > Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies(41 Haematology and Blood Transfusion / Hamatologie und Bluttransfusion)
Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies(41 Haematology and Blood Transfusion / Hamatologie und Bluttransfusion)

Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies(41 Haematology and Blood Transfusion / Hamatologie und Bluttransfusion)

          
5
4
3
2
1

Out of Stock


Premium quality
Premium quality
Bookswagon upholds the quality by delivering untarnished books. Quality, services and satisfaction are everything for us!
Easy Return
Easy return
Not satisfied with this product! Keep it in original condition and packaging to avail easy return policy.
Certified product
Certified product
First impression is the last impression! Address the book’s certification page, ISBN, publisher’s name, copyright page and print quality.
Secure Checkout
Secure checkout
Security at its finest! Login, browse, purchase and pay, every step is safe and secured.
Money back guarantee
Money-back guarantee:
It’s all about customers! For any kind of bad experience with the product, get your actual amount back after returning the product.
On time delivery
On-time delivery
At your doorstep on time! Get this book delivered without any delay.
Notify me when this book is in stock
Add to Wishlist
X

About the Book

Acute Leukemias IX provides an extended and thorough overview of recent developments in cell biology and experimental therapy for acute leukemias. Following the tradition of the Acute Leukemias series since 1987, this book bridges the gap between basic research and clinical studies and emphasizes that both aspects are equally necessary to achieve improvements, not only in understanding the disease but also in providing better therapy. As a forum for world-wide activities in the field of acute leukemias the volume contains invaluable contributions that provide the reader with new, previously unpublished information

Table of Contents:
Epidemiology and Classification.- The New WHO Classification for Acute Myeloid Leukemias and Myelodysplastic Syndromes.- How Representative is the GMALL of the German Population?.- Philadelphia Chromosome-Positive Mature B-Cell (Burkitt Cell) Leukemia.- 8-Years Experience of Ukrainian Reference Laboratory for Diagnosis of Acute Leukemias in Children.- Establishment of the B-Cell Precursor-Acute Lymphoblastic Leukemia Cell Line MUTZ-5 Carrying a (12;13) Translocation.- Molecular Genetics, Transcription Factors and Signaling.- The t(8;21), t(12;21), and inv(16) Fusion Proteins Contact Co-Repressors and Histone Deacetylase to Repress Transcription.- Disturbed Differentiation of AML1/ETO Transduced Human CD34+ Progenitors.- Inducible AML1/ETO Expression in U-937 Myeloid Cells: A Model to Identify Genes Targeted by the Leukemia-Specific Fusion Protein.- Mix and Match Gene Fusions with TEL and AML1.- Transcriptional Repression of C/EBP? by Histone Deacetylases in Acute Myeloid Leukemia.- Biology of Transcription Factor GATA-2 in Normal and Leukaemic Haematopoiesis.- Retinoic Acid in Myeloid Differentiation and Acute Promyelocytic Leukemia (APL).- Combined Arsenic Trioxide and GM-CSF Induces Differentiation in Retinoic Acid (RA)-Sensitive as well as -Resistant APL Cells by Modulating Jak2 Kinase.- Different Mechanisms Lead to Rearrangements of the MLL Gene in Cases with Acute Myeloid Leukemia (AML) and Translocation t(10;ll).- Genes Specifically Expresssed in Monocytic AML Cells Identified bv Array Technology.- Oncogenic Activation of Growth Factor Signals in AML.- Establishment of Inducible Expression Systems to Study the Role of STAT-Transcription Factors in AML.- Farnesyltransferase Inhibitors in Leukemia.- Therapeutic Strategies that Overcome Resistance to Nucleoside Analogues: Dysregulating Checkpoint Response and Survival Pathways by UCN-01.- Imatinib (ST1571) for the Treatment of Chronic Myelogenous Leukemia (CML).- Leukemia Stem Cells.- The Stem Cell Leukaemia Gene: A Critical Regulator of Haemopoiesis and Vasculogenesis.- Establishment of the Two Cytokine-Dependent Acute Myeloid Leukemia-Derived Cell Lines MUTZ-8 and MUTZ-11.- Leukemia Stem Cells with Efficient Drug Efflux in Acute Myeloid Leukemia.- Growth of Leukemic Progenitor Cells of Acute Lymphoblastic Leukemia in Co-Culture with Murine Stromal Cell Line MS-5.- Reduced Level of Philadelphia Chromosome Positive (Ph+) Cells in Lineage Negative Side Population Bone Marrow Progenitor Cells from Patients with Chronic Myeloid Leukemia (CML).- Developmental Therapeutics.- New Developmental Agents and Directions in the Treatment of Acute Myelogenous Leukemia.- Investigational Therapy in Acute Myeloid Leukemia: 2001.- CMA-676: Mechanisms of Action and Clinical Results.- Mylotarg Therapy in Acute Myeloid Leukemia: Mechanism of Action and Implications for Future Treatment Protocols.- Antibody-Based Therapy of Myeloid Leukemia.- Anti-angiogenic Therapy in Acute Myeloid Leukemia.- 8-Chloro-cAMP Serves as a Prodrug for the RNA Directed Nucleoside Analog, 8-Chloro-Adenosine.- Pharmacokinetics and Pharmacodynamics of Daunoxome in Acute Myeloid Leukemia Patients.- Drug Resistance, Apoptosis.- Modulation of Multidrug Resistance in Acute Myeloid Leukemia.- Proliferative Activity of Leukemic Blasts and Cytosine Arabinoside Pharmacodynamics are Associated with Cytogenetically Defined Prognostic Subgroups in Acute Myeloid Leukemia.- No Evidence of MDR1 Gene Related Clonal Selection in Relapsed or Refractory Acute Myeloid Leukemia (AML).- The Role of Mutations in the Deoxycytidine Kinase (dCK) Gene in the Development of Acute Myeloid Leukemia (AML) Towards Relapsed and/or Refractory Disease.- Quantitative Determination of Bcl-2 Expression in AML Cell Lines and in Normal and Leukemic Progenitor Cell Compartments by Laser Scanning Cytometry: Comparison with Flow Cytometry and Western Blot.- Apoptosis of Peripheral Blood Leukocytes in Children Survived from Acute Lymphoblastic Leukemia.- In Vitro Sensitivity to Chemotherapy-Induced Apoptosis in CD2-positive and CD2-negative Childhood T-ALL.- A Systematic Approach to the Dissection of Apoptotic Blockades in Treatment-Refractory Acute Myeloid Leukemias.- GM-CSF is the Mediator of the Proliferative Effect of Tumor Necrosis Factor Alpha in Acute Myeloid Leukemia-Derived Cell Lines.- Acute Myeloid Leukemias Differ at Primary Diagnosis and Relapse in Endogenous Proliferative Activity, Response to Stimulation by Exogenous G-CSF and GM-CSF and Production of G-CSF.- Etoposide Induces Transition of 14-3-3 from the Cytoplasma into the Nucleus where it Binds to Topoisomerase II.- The CCC-Assay: A New Assay for Characterization of Leukaemic Cells Surviving Chemotherapy In-Vitro.- Resistance to Drug-Induced Cytotoxicity in Acute Myeloid Leukemia is Significantly Correlated Between Inhibitors of Topoisomerase I and II and Nucleoside Analogues.- Age-Related Differences in Cellular Drug Resistance in Children with Acute Myeloid Leukemia (AML).- Prognostic Factors, Minimal Residual Disease.- FLT3 Length Mutations and MLL-Duplications in AML: Correlation to Cytogenetics, FAB-Subtype, and Prognosis.- Identification of Partial Tandem Duplications of the MLL Gene in Acute Myeloid Leukemia: Prospective Analysis within the Multicenter Treatment Trial AML HD98-A.- Single-Center Retrospective Analysis of Prognosis of 138 Patients Older than 55 Years with Acute Myeloid Leukemia.- Acute Myeloid Leukemia in Elderly Patients: Prognostic Value of Bone Marrow Aspirate on 14th Day of Induction Treatment.- Simultaneous Monitoring of Minimal Residual Disease by RT-PCR of PML/RARa and RARa/PML Fusion Transcripts in Acute Promyelocytic Leukemia (APL).- Cytogenetic Studies and Cell Cycle Parameters in Acute Lymphoblastic Leukemia (ALL) in Children.- Reliability of BCR-ABL RT-PCR in Adult B-Lineage Lymphoblastic Leukemia: Results of Confirmational PCR.- Evaluation of Minimal Residual Disease (MRD) in Children with T-Lineage Acute Lymphoblastic Leukemia.- Evaluation of Minimal Residual Disease (MRD) in Children with B-Cell Acute Lymphoblastic Leukemia During Maintenance of Remission.- Frequency of Cytogenetic Aberrations and their Influence on Results of Treatment in Childhood Acute Lymphoblastic Leukemia (ALL).- Evaluation of Minimal Residual Disease (MRD) in Children with B-Cell Acute Lymphoblastic Leukemia after Completion of Induction Therapy.- Evaluation of Minimal Residual Disease using PCR.- Treatment of AML.- Biology Based Treatment Strategies for Acute Myeloid Leukemia.- Cytogenetics for Treatment Stratification in de novo Adult Acute Myeloid Leukemia.- Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach.- Therapy of Newly Diagnosed Acute Promyelocytic Leukemia. Results of the AMLCG.- FS-HAI for Relapsed AML.- Treatment of AML and High-Risk MDS at M.D. Anderson: The Lone Star Approach.- Long Remissions after Late Relapse of Acute Myeloid Leukaemia (AML) with Idarubicin + Cytarabine Conventional Doses Treatment.- Outcome of Patients with Refractory/Recurrent Acute Myelogenous Leukaemia (AML) Treated at a Single Centre.- Phase I Clinical Evaluation of Topotecan Combined with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia.- 7+3+VP-16 as Remission Induction/Consolidation and Two Types of Maintenance in Adult AML: 8 Years Results of Russian Multicenter Trial.- Interferon-? plus ATRA Maintenance in High Risk AML.- Weekly Oral Idarubicin: An Ambulatory Treatment of Acute Myeloid Leukemia in Poor-Risk Elderly Patients.- Treatment of Relapsed AML of Childhood with Daunoxome-FLAG (Liposomal Daunorubicin, Fludarabine, High-Dose Cytarabine and G-CSF).- Treatment of AML.- ALL HRG-Experience with Modified New York Regimen.- Prospective, Multicenter Study of CNS-Toxicity and Health-Related Quality of Life in ALL-Patients.- Limited Success with a Postremission Strategy Comprising Conventional Consolidation and High-Dose Treatment (HDT) with Autologous Peripheral Progenitor Cell (PBPC) Support for Adult Acute Lymphoblastic Leukaemia (ALL).- Single High-Dose Idarubicin in Advanced Acute Lymphoblastic Leukaemia: Clinical and Pharmacokinetics Results.- Salvage Therapy for Resistant or Relapsing Acute Lymphoblastic Leukemia (ALL) after Idarubicin-Based Induction.- Transplantation and Cellular Immune Therapy.- Transplantation Strategies for High Risk Acute Myeloid Leukemias.- Current Role of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation in Patients with AML.- Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.- Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia.- Adoptive Immunotherapy in Chimeras - Donor Lymphocyte Transfusions for the Treatment of Acute Myeloid Leukemia.- Herpes Simplex Virus Thymidine Kinase-Transduced Human T Lymphocytes.- Interferon Alpha and Gamma Differentially Alter the Susceptibility of Tumor Cells to Lysis by MHC-Restricted and Non-MHC-Restricted Cytotoxic Effector Cells.- Targeting Acute Leukemia and Cancer by High-Affinity T-Cell-Receptor Transfer.- Nonmyeloablative Conditioning Regimen in Patients with High-Risk Acute Myeloid Leukemia: Unrelated and Sibling Allogeneic Hematopoietic Stem Cell Transplantation.- Induction of Mixed Chimerism in Patients after Non-Myeloablative Stem Cell Transplantation (SCT) for High-Risk Haematological Malignancies.- Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) Immediately after Intensive Cytoreduction for High-Risk Myeloid Leukemias.- Allogeneic Stem Cell Transplantation (HSCT) for Secondary Acute Leukemia Following MDS.- Biology of Stem Cell Mobilization Induced by Cytokines.- Feasibility of High Dose Melphalan (140 mg/m2) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission.- Opportunistic Infections.- Strategies for Empiric Antifungal Therapy in Neutropenic Patients.- Acute Leukemias: Management of Infections.- Leukopenia is no Risk Factor for Phlebitis Associated with Peripheral Teflon Catheters.- PCR-Mediated Detection of Aspergillus Species in Bronchoalveolar Lavage Samples of Febrile Neutropenic Patients with Acute Leukemias: Clinical Results.- Interleukin-8, Interleukin-6 and C-Reactive Protein Serum Concentrations in Acute Leukemia Patients without and with Clinical Symptoms of Infection.- Supportive Care and Quality of Life.- Update on Antiemetic Strategies.- Quality of Life and Coping in Patients with Acute Myeloid Leukemia (AML).- Helping Patients Deal with Sexual Difficulties During and after Cancer Treatment.- Sperm Quality May be Impaired in Long-Term Acute Myeloid Leukemia Survivors after Chemotherapy.


Best Sellers


Product Details
  • ISBN-13: 9783540439714
  • Publisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
  • Publisher Imprint: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • Height: 235 mm
  • No of Pages: 621
  • Series Title: 41 Haematology and Blood Transfusion / Hamatologie und Bluttransfusion
  • Sub Title: Basic Research, Experimental Approaches and Novel Therapies
  • Width: 155 mm
  • ISBN-10: 3540439714
  • Publisher Date: 13 Feb 2003
  • Binding: SA
  • Language: English
  • Returnable: N
  • Spine Width: 242 mm
  • Weight: 1020 gr


Similar Products

How would you rate your experience shopping for books on Bookswagon?

Add Photo
Add Photo

Customer Reviews

REVIEWS           
Click Here To Be The First to Review this Product
Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies(41 Haematology and Blood Transfusion / Hamatologie und Bluttransfusion)
Springer-Verlag Berlin and Heidelberg GmbH & Co. KG -
Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies(41 Haematology and Blood Transfusion / Hamatologie und Bluttransfusion)
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies(41 Haematology and Blood Transfusion / Hamatologie und Bluttransfusion)

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book
    Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    New Arrivals


    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!
    ASK VIDYA